Moneycontrol Bureau
Shares of Suven Life Sciences rallied more than 4 percent intraday Monday as the pharma company has initiated multiple ascending dose (MAD) studies in phase-I clinical trial.
"Suven has completed the single ascending dose (SAD) studies of SUVN-G3031 in healthy human volunteers and initiated multiple ascending dose studies (MAD) as a part of the phase I study currently ongoing in USA under US-IND 123179," said the company in its filing to the exchange.
SUVN-G3031 is a potent, selective, brain penetrant and orally active Histamine H3 inverse agonist being developed for the treatment of cognitive dysfunction associated with alzheimer’s disease and schizophrenia.
Suven said the phase-1 study was designed to evaluate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy volunteers. "The tolerability of SUVN-G3031 up to the highest dose administered in SAD study is excellent. No serious adverse events occurred. SUVN-G3031 demonstrated excellent pharmacokinetics with a potential for once in a day dosing," it added.
At 12:40 hours IST, the scrip of Suven Life Sciences was quoting at Rs 324.65, up Rs 6.90, or 2.17 percent on the BSE.
Posted by Sunil Shankar Matkar
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
